Key result
Alpha-glucosidase inhibitors improve postprandial endothelial dysfunction and may prevent cardiovascular events by controlling postprandial hyperglycemia without increasing insulin secretion.
Why the study?
Do α-glucosidase inhibitors prevent cardiovascular disease and improve endothelial function in patients with postprandial hyperglycemia?
Do α-glucosidase inhibitors prevent cardiovascular disease and improve endothelial function in patients with postprandial hyperglycemia?
This review highlights the potential of α-glucosidase inhibitors to improve endothelial function and prevent cardiovascular events by targeting postprandial hyperglycemia.
Hypothesis-generating for α-glucosidase inhibitors in postprandial hyperglycemia; randomized trials needed before clinical adoption.
Glucose spikes after meals induce endothelial dysfunction, which may lead to progression of atherosclerosis and cardiovascular events. Controlling postprandial hyperglycemia should be the potential target for preventing cardiovascular events. In clinical settings, the α-glucosidase inhibitors (α-GIs) glinides are often prescribed to prevent postprandial hyperglycemia. Recent studies have showed that α-GIs may have incretin-like effects and other pleiotropic effects. This review will describe the endothelial function associated with postprandial hyperglycemia, and will discuss the effects of α-GIs on preventing cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2014) conducted a review in Type 2 Diabetes Mellitus and Postprandial Endothelial Dysfunction. Alpha-glucosidase inhibitors (acarbose, miglitol) was evaluated. Alpha-glucosidase inhibitors improve postprandial endothelial dysfunction and may prevent cardiovascular events by controlling postprandial hyperglycemia without increasing insulin secretion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: